Skip to main content
SpringerLink
Log in

HPV-Impfung

  • Chapter
Kolposkopie in der Praxis

  • 1610 Accesses

Zusammenfassung

Eine Impfung gegen humane Papillomaviren bietet die einzigartige Möglichkeit, die Manifestation der HPV-bedingten Präkanzerosen vollständig zu verhindern. Sie wird aber die sekundäre Prävention, zu der Zytologie und Kolposkopie gehören, auf absehbare Zeit nicht überflüssig machen. Vielmehr ergeben sich neue Herausforderungen für diese etablierten Verfahren.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Albring C, Harlfinger W (2007) Kompetenz und Vertrauen stärken (Editorial). Frauenarzt 48:417

    Google Scholar 

  • Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346: f 2032

    Google Scholar 

  • Bharadwaj M, Hussain S, Nasare V, Das BC (2009) HPV & HPV vaccination: issues in developing countries. Indian J Med Res 130:327–333

    Google Scholar 

  • Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM (2011) Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377: 2085 –2092

    Google Scholar 

  • Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Brit J Cancer 105: 28–37

    Google Scholar 

  • Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC (2010) Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Brit J Cancer 102: 1129 –1136

    Google Scholar 

  • de Sanjose S, Quint WG, Alemany L et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048– 1056

    Google Scholar 

  • Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G (2009) Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5:705–719

    Google Scholar 

  • FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915–1927

    Google Scholar 

  • Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928–1943

    Google Scholar 

  • Garnett GP, Waddell HC (2000) Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 19:101–111

    Google Scholar 

  • Gross G, Gissmann L, Hillemanns P, Ikenberg H, Kaufmann AM, Petry KU, Pfister H, Schneede P, Schneider A, Smola S (2010) Die Impfprävention HPV-assoziierter Neoplasien – eine Zusammenfassung der deutschen S3-Leitlinie. Deutsche Medizinische Wochenschrift 135: 1083 –1086

    Google Scholar 

  • Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743–753

    Google Scholar 

  • Hillemanns P (2013) HPV-Impfstoff der zweiten Generation gegen neun Virustypen gerichtet. Deutsches Ärzteblatt 110:2479–2480

    Google Scholar 

  • Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM (2012) Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 344:e1401

    Google Scholar 

  • Kang WD, Choi HS, Kim SM (2013) Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 130(2):264–268

    Article  CAS  PubMed  Google Scholar 

  • Kaufmann AM, Nieland JD, Jochmus I et al. (2007) Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121: 2794 –2800

    Google Scholar 

  • Kling M, Zeichner JA (2010) The role of the human papillomavirus (HPV) vaccine in developing countries. Int J Dermatol 49:377–379

    Google Scholar 

  • Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonzalez P, Solomon D, Jimenez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 103: 1444 –1451

    Google Scholar 

  • Lehtinen M, Paavonen J, Wheeler CM et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89–99

    Article  CAS  PubMed  Google Scholar 

  • Naud P, Roteli-Martins CM, De Carvalho N (2011) HPV-16/18 vaccine: sustained immunogenicity and efficacy to 9.4 years. Abstract No O-1804. 27th International Papillomavirus Conference, 17.–22. Sept. 2011, Berlin

    Google Scholar 

  • Paavonen J, Jenkins D, Bosch FX et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161 –2170

    Google Scholar 

  • Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually transmitted infections 87: 544–547

    Google Scholar 

  • Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D (2012) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 8:390–397

    Google Scholar 

  • Schneider A, Hammerschmidt T, Schwarz TF, Rogoza RM, Ferko N, Siebert U (2007) Langfristige Public-Health-Effekte einer Impfung gegen Zervixkarzinom in Deutschland. Geburtsh Frauenheilk 67:850–858

    Google Scholar 

  • Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjose S (2012) Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 7:38

    Article  Google Scholar 

  • Stanley M (2012) Perspective: Vaccinate boys too. Nature 488 : S10

    Google Scholar 

  • Strasser T (1978) Reflections on cardiovascular diseases. Interdisciplinary Science Review 3:225–230

    Google Scholar 

  • Sutton I, Lahoria R, Tan I, Clouston P, Barnett M (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15:116–119

    Google Scholar 

  • Wheeler CM, Kjaer SK, Sigurdsson K et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199:936–944

    Google Scholar 

  • Wick DA, Webb JRA (2011) novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine 29: 7857 – 7866

    Google Scholar 

  • zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:260–265

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik, Münster

    Univ.-Prof. Dr. med. Ralph J. Lellé

  2. Zytologisches Labor, Dysplasie Sprechstunde, Düsseldorf

    PD Dr. med. Volkmar Küppers

Authors
  1. Univ.-Prof. Dr. med. Ralph J. Lellé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. med. Volkmar Küppers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lellé, R., Küppers, V. (2014). HPV-Impfung. In: Kolposkopie in der Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38308-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-38308-3_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-38307-6

  • Online ISBN: 978-3-642-38308-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation